





Divergent Total Synthesis of Alkaloids from the Pentacyclic *Aspidosperma* Skeleton



TJD group meeting
11/03/2014


Alice Gatland






1) **(+)-fendleridine**

enantiomeric
series




pentacyclic *Aspidosperma*
alkaloid skeleton


1



3) **(-)-kopsifoline D**



4) **(-)-deoxoapodine**




2) **kopsinine**



Synthesis of Pentacyclic Skeleton (1)





- Key step: [4+2]/[3+2] cycloaddition cascade to form pentacyclic system and set stereochemistry.




pentacyclic *Aspidosperma*
alkaloid skeleton

1

[4+2], -N₂, [3+2]




Synthesis of Acid Fragment (4)





Synthesis of 1,3,4-oxadiazole 3

- 1-Benzyltryptamine (**5**) prepared according to literature procedure.




Pentacycle Synthesis







1) (+)-fendleridine




racemic
1






NH_3, MeOH




TFAA, pyr.

90%
(2 steps)




HF-pyridine

THF, 0 °C
quant.



Na-selectride


THF
85%



Na-selectride = $\text{NaBH}(\text{s-Bu})_3$


$\text{NaH}, \text{CS}_2, \text{MeI}$
THF, 0 °C to r.t.

92%




AIBN, Bu_3SnH

PhMe, 100 °C
77%




Lawesson's reagent


PhMe, 60 °C
85%






*then chiral separation
by chromatography*





Lawesson's reagent






1) (+)-fendleridine













racemic
1



2) kopsinine









1) (+)-fendleridine

enantiomeric
series




pentacyclic *Aspidosperma*
alkaloid skeleton

1









3) (-)-kopsifoline D





2) kopsinine







1) LDA, PhSeCl **81%**
2) *m*-CPBA **90%**



1) TBAF **98%**
2) Et₃N, MsCl
then NaI **68%**




then chiral separation




1) (+)-fendleridine

enantiomeric series




pentacyclic *Aspidosperma*
alkaloid skeleton


1





2) kopsinine







4) (-)-deoxoapodine






3) (-)-kopsifoline D






then chiral separation






4) (-)-deoxoapodine




1) (+)-fendleridine

enantiomeric series




pentacyclic *Aspidosperma*
alkaloid skeleton

1



3) (-)-kopsifoline D



2) kopsinine

